Valneva Management
Management criteria checks 1/4
Valneva's CEO is Thomas Lingelbach, appointed in May 2013, has a tenure of 11.58 years. total yearly compensation is €919.56K, comprised of 58.8% salary and 41.2% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $861.86K. The average tenure of the management team and the board of directors is 1 years and 1.8 years respectively.
Key information
Thomas Lingelbach
Chief executive officer
€919.6k
Total compensation
CEO salary percentage | 58.8% |
CEO tenure | 11.6yrs |
CEO ownership | 0.2% |
Management average tenure | less than a year |
Board average tenure | 1.8yrs |
Recent management updates
Recent updates
Valneva seeking a partnership for next-gen COVID-19 vaccine
Sep 26Valneva shows booster effect of COVID shot against AstraZeneca vaccine
Aug 29Valneva launches up to $75M at-the-market ADS offering program
Aug 15Valneva: Vaccine Business, Catalysts Ahead, And Pfizer's Lyme Love
Aug 08Valneva agrees to cut COVID vaccine supplies to EU
Jul 20CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -€7m |
Jun 30 2024 | n/a | n/a | -€32m |
Mar 31 2024 | n/a | n/a | -€24m |
Dec 31 2023 | €920k | €541k | -€101m |
Sep 30 2023 | n/a | n/a | -€113m |
Jun 30 2023 | n/a | n/a | -€7m |
Mar 31 2023 | n/a | n/a | -€135m |
Dec 31 2022 | €784k | €525k | -€143m |
Sep 30 2022 | n/a | n/a | €73m |
Jun 30 2022 | n/a | n/a | -€159m |
Mar 31 2022 | n/a | n/a | -€72m |
Dec 31 2021 | €769k | €420k | -€73m |
Sep 30 2021 | n/a | n/a | -€248m |
Jun 30 2021 | n/a | n/a | -€125m |
Mar 31 2021 | n/a | n/a | -€91m |
Dec 31 2020 | €649k | €376k | -€64m |
Sep 30 2020 | n/a | n/a | -€62m |
Jun 30 2020 | n/a | n/a | -€25m |
Mar 31 2020 | n/a | n/a | -€8m |
Dec 31 2019 | €1m | €384k | -€2m |
Sep 30 2019 | n/a | n/a | €4m |
Jun 30 2019 | n/a | n/a | €1m |
Mar 31 2019 | n/a | n/a | €7m |
Dec 31 2018 | €694k | €377k | €3m |
Sep 30 2018 | n/a | n/a | -€7m |
Jun 30 2018 | n/a | n/a | -€7m |
Mar 31 2018 | n/a | n/a | -€8m |
Dec 31 2017 | €649k | €367k | -€11m |
Compensation vs Market: Thomas's total compensation ($USD958.78K) is below average for companies of similar size in the US market ($USD2.15M).
Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.
CEO
Thomas Lingelbach (61 yo)
11.6yrs
Tenure
€919,563
Compensation
Mr. Thomas Lingelbach has been the Chief Executive Officer of Valneva SE since May 2013 and served as its Chairman and Member of the Management Board since May 10, 2013 until December 20, 2023 and serves a...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 11.6yrs | €919.56k | 0.24% $ 861.9k | |
Chief Financial Officer | no data | €558.83k | 0.028% $ 100.0k | |
Chief Business Officer | less than a year | €401.34k | 0.39% $ 1.4m | |
Chief Medical Officer | less than a year | €539.76k | 0.028% $ 100.0k | |
Chief Commercial Officer | less than a year | €516.75k | no data | |
Chief Operating Officer | no data | no data | no data | |
Chief Scientific Officer | less than a year | no data | no data | |
Vice President of Investor Relations | 3.4yrs | no data | no data | |
VP of Global Communications & European Investor Relations | no data | no data | no data | |
Chief People Officer | less than a year | no data | no data | |
Head of Global Medical Affairs | no data | no data | no data | |
Head of Clinical Operations | no data | no data | no data |
1.0yrs
Average Tenure
53yo
Average Age
Experienced Management: VALN's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | less than a year | €919.56k | 0.24% $ 861.9k | |
Director | less than a year | €74.07k | 0.019% $ 67.9k | |
Member of Scientific Advisory Board | 4.9yrs | €10.00k | no data | |
Director | less than a year | €66.11k | no data | |
Director | less than a year | €28.25k | no data | |
Director | less than a year | no data | no data | |
Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
Chair of Scientific Advisory Board | 5.4yrs | €2.92k | no data | |
Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
Chairman | less than a year | €74.30k | 0.0088% $ 31.9k | |
Member of Scientific Advisory Board | 2.6yrs | no data | no data | |
Member of Scientific Advisory Board | 2.6yrs | no data | no data |
1.8yrs
Average Tenure
65yo
Average Age
Experienced Board: VALN's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/27 08:54 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Valneva SE is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Stéphan Dubosq | Arkeon Finance |
Jean-Jacques Le Fur | Bryan Garnier & Co |
Bruno Bulic | Bryan Garnier & Co |